Clinuvel - Latest News [Page 1]

CLINUVEL Progresses Innovative DNA Repair Program

Thursday, 10 September 2020, 6:39 pm | Clinuvel

Drug tested to protect skin and regenerate DNA, firstly in XP patients at 10,000-fold skin cancer risk CLINUVEL PHARMACEUTICALS LTD today announced the progression of its drug SCENESSE® (afamelanotide 16mg) to treat the disease xeroderma pigmentosum ... More >>

Clinuvel records first A$1 million in sales

Monday, 27 June 2011, 3:33 pm | Clinuvel

Clinuvel Pharmaceuticals Limited ( ASX: CUV; XETRA-DAX: UR9; ADR: CLVLY ) today announced that it has made a successful start to its distribution of its new drug SCENESSE® (afamelanotide) to the erythropoietic protoporphyria (EPP) patient community in Italy. More >>

UV-protective drug to be tested for vitiligo

Wednesday, 25 August 2010, 11:53 am | Clinuvel

A drug initially developed to protect skin from light and UV will soon be tested as a repigmentation therapy in vitiligo, a common disorder which causes skin to gradually lose its pigment or tone. SCENESSE?, a new drug developed in Australia, will be evaluated ... More >>